Immunization as an Investment Attraction Point: How Will the Pandemic Change the Vaccine Development Market as a Whole?
The pandemic has tested the immunization industry worldwide, and given it a new impetus. It has given rise to a trend of making next-generation vaccines which are safe, simple to produce, and potentially more universal. Today, enormous investment opportunities are helping to build new markets. These could help usher in a secure future – one in which innovative technologies are used to prevent new epidemics, new vaccines are employed in other areas of immunology, and effective efforts are made to combat new strains, serious infectious diseases, and a whole range of tropical diseases. According to analysts from Morgan Stanley and Credit Suisse, the future coronavirus vaccine market may be worth over USD 10 billion a year. It is too early to forecast income from new vaccines, or to assess the impact the pandemic had on the vaccine market as a whole. However, regardless of whether the pandemic will impact only the current state of the vaccine market or will drive global changes in the future, COVID-19 provided the stimulus for opening new horizons in research and development. How will the pandemic impact the capacity of the global vaccine market? Will COVID-19 become a driver of global change on the market, and what criteria and risks may impact how attractive the vaccine development market will appear to investors in the future? Will projects related to virus research, the development of new platforms, and infectious disease prevention be more heavily financed? How might therapeutic vaccines prevent the spread of infection, and what is the risk of antimicrobial resistance? What innovative developments and severe disease-prevention technologies will offer the greatest promise for investment? Will pharma and biotech industries come to be viewed as more stable for investment?
Dmitry Khalilov, Partner, Life Sciences & Health Leader, Central, Eastern and Southeastern Europe & Central Asia, EY
Igor Borisevich, Deputy Head, Federal Medical-Biological Agency of the Russian Federation
Jai Verma, Chairman, Chief Executive Officer, Protecti Global Holdings, Ltd
Oleg Gridnev, Deputy Minister of Health of the Russian Federation
Ann Egede Ottosen, Senior Manager of Supply Division, United Nations Children's Fund
Vladimir Khristenko, President, Nanolek
Mikhail Tsyferov, President, Member of the Board of Directors, Petrovax Pharm
Front row participant
Alexander Plakida, Chairman of the Governing Board, National Network of the Global Compact Association